EDUCATION AND TRAINING

PhD, Biomedical Science with a focus in Virology (Icahn Graduate School of Biomedical Sciences at Mount Sinai)

BIOGRAPHY

Mark earned his PhD in the tenOever Lab at the Icahn Graduate School of Biomedical Sciences at Mount Sinai in 2013. He then joined Acorda Therapeutics as a Research Associate, developing screening techniques for novel peptides from phage display libraries. As Senior Scientist at Autonomous Therapeutics Inc., he contributed to the development of novel interfering particle therapeutics targeting influenza. He later became the Director of Research at CytoDel Inc., where he led efforts to develop and assess the efficacy of novel botulism neurotoxin derivatives. In 2025, Mark came full circle—returning to the tenOever lab once again, now at NYU Langone, in his current role as Senior Scientist.